Related Experiment Video
Updated: Oct 14, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Gene signatures with therapeutic value: emerging perspective for personalized immunotherapy in renal cancer
Pankaj Ahluwalia1, Ashis K Mondal1, Nikhil S Sahajpal1
1Department of Pathology, Medical College of Georgia, Augusta University, GA 30912, USA.
Abstract:
Renal cancer is one of the deadliest urogenital diseases. In recent years, the advent of immunotherapy has led to significant improvement in the management of patients with renal cancer. Although cancer immunotherapy and its combinations had benefited numerous patients, several challenges need to be addressed. Apart from the high costs of treatment, the lack of predictive biomarkers and toxic side-effects have impeded its wider applicability. To address these issues, new biomarkers are required to predict responsiveness and design personalized treatment strategies. Recent advances in the field of single-cell sequencing and multi-dimensional spatial transcriptomics have identified clinically relevant subtypes of renal cancer. Furthermore, there is emerging potential for gene signatures based on immune cells, non-coding RNAs, and pathways such as metabolism and RNA modification. In this review article, we have discussed recent progress in the identification of gene signatures with predictive and prognostic potential in renal cancer.
Insights
New gene signatures show promise for predicting renal cancer treatment response. Identifying these biomarkers could personalize therapy and overcome challenges like cost and side effects.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Renal cancer poses a significant threat, with immunotherapy improving patient outcomes.
- Challenges remain, including high treatment costs, lack of predictive biomarkers, and adverse effects.
- Personalized treatment strategies require novel biomarkers for predicting immunotherapy response.
Purpose of the Study:
- To review recent advancements in identifying gene signatures for renal cancer.
- To highlight the predictive and prognostic potential of these gene signatures.
- To discuss emerging biomarkers including immune cells, non-coding RNAs, and metabolic pathways.
Main Methods:
- Review of recent literature on gene signatures in renal cancer.
- Analysis of advances in single-cell sequencing and spatial transcriptomics.
- Exploration of potential biomarker sources like immune cells, non-coding RNAs, and metabolic pathways.
Main Results:
- Single-cell sequencing and spatial transcriptomics have revealed clinically relevant renal cancer subtypes.
- Emerging gene signatures show potential based on immune cells, non-coding RNAs, and metabolic/RNA modification pathways.
- These signatures offer predictive and prognostic value for renal cancer management.
Conclusions:
- Gene signatures hold significant potential for predicting renal cancer patient response to immunotherapy.
- Further research into these biomarkers can facilitate personalized treatment strategies.
- Addressing challenges in biomarker discovery is crucial for wider immunotherapy applicability in renal cancer.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy